The purpose of this research study is to find out what effects (good and bad) that omega-3
fatty acids has on schizophrenia.
The two aims of the study test the hypotheses that correcting omega-3 fatty acid deficiency
in the early stages of schizophrenia improves positive symptom treatment response, negative
symptom treatment response, and cognition symptom response.
- Between the ages of 8-25 years.
- Diagnosis of MDD and not exhibited symptom remission CDRS-R (> 28 but < 40) despite
being administered a standard therapeutic dose of an SSRI continuously for a minimum
of 6 weeks.
- Ability and willingness to provide assent and informed, written consent from at least
one biological parent.
- Present with biological parent or legal guardian.
- Willingness to maintain current dietary habits.
- Permission from treating physician
- Able to perform fMRI/MRS.
- Inability or unwillingness to provide consent.
- Antecedent or concurrent serious medical illness.
- Clinically unstable medical disease, including cardiovascular, hepatic insufficiency,
severe renal impairment, gastrointestinal, pulmonary, metabolic, endocrine, obesity
or other systemic disease.
- History of seizures, excluding febrile seizures in childhood.
- Patients requiring treatment with any drug which might obscure the action of the
- Female patients who are either pregnant or lactating.
- Clinically significant laboratory abnormalities in the last year on CBC or TSH tests.
- Judged clinically to be at suicidal risk (defined as having active suicidal ideation,
intent or plan, or a serious suicide attempt within the past 6 months, or a baseline
CDRS-R suicide score of >3).
- Hospitalized within the last 3 months
- Greater than 1 year outside appropriate age/grade level
- Cerebral aneurysm clip
- Cochlear implant
- Metal fragments lodged within the eye or braces
- Necessity of sedation (no sedation will be given).
- History of loss of consciousness > 10 minutes in duration
- Allergy to seafood.